Using mid range guidance these are my calculations:
Revenue EBITDA NPAT EV/EBITDA DEBT/EBITDA Share price (PE 12) 1 $222M $74.5M $31.8M 5.91 0.85 $1.27
This is a very strong position and probably conservative considering ACF normally achieve/exceed upper guidance. That level of DEBT/EBITDA provides the opportunity for another decent acquisition.
They have a further $15M of debt headroom. They could access this and still remain within their DEBT/EBITDA target. Add $6M cash at bank and we are looking at consideration of up to $21m. At a 3.8x multiple that is a company with $5.5M EBITDA and around $14M annual revenue.
Only 2 days until results are released.
- Forums
- ASX - By Stock
- Ann: FY24 Results Reporting Date and Conference Call Details
ACF
acrow limited
Add to My Watchlist
2.02%
!
$1.01

Using mid range guidance these are my...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$1.01 |
Change
0.020(2.02%) |
Mkt cap ! $311.0M |
Open | High | Low | Value | Volume |
99.0¢ | $1.01 | 99.0¢ | $135.4K | 136.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
7 | 48880 | $1.00 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.01 | 52292 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
7 | 48880 | 1.000 |
2 | 3272 | 0.995 |
3 | 13362 | 0.990 |
3 | 11959 | 0.985 |
1 | 14542 | 0.980 |
Price($) | Vol. | No. |
---|---|---|
1.010 | 52292 | 5 |
1.015 | 9025 | 1 |
1.020 | 38181 | 3 |
1.025 | 2850 | 1 |
1.030 | 11499 | 2 |
Last trade - 10.43am 04/07/2025 (20 minute delay) ? |
Featured News
ACF (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
Previous Video
Next Video
SPONSORED BY The Market Online